key: cord-0814058-v6di48uy
authors: Aguila, Enrik John T.; Lontok, Marie Antoinette D. C.; Aguila, Eliezer James T.
title: Letter: role of probiotics in the COVID‐19 pandemic
date: 2020-08-14
journal: Aliment Pharmacol Ther
DOI: 10.1111/apt.15898
sha: 65cc67f64c3277dbbee9418b179678c17ad17c1c
doc_id: 814058
cord_uid: v6di48uy

LINKED CONTENT This article is linked to Tian et al and Tian and Rong papers. To view these articles, visit https://doi.org/10.1111/apt.15731 and https://doi.org/10.1111/apt.15931

Editors,

We have read with great interest the review article by Dr. Tian et al 1 . Being one of the earliest publications reviewing the impact of COVID-19 on the GI system, it has paved the way for further studies. We are particularly interested in the possible use of probiotics among patients with COVID-associated diarrhoea.

While there is still no recommendation regarding probiotics in the treatment of COVID-19 until now, we wish to highlight the available evidence regarding its potential benefits during the pandemic.

Probiotics are living microorganisms that when administered in sufficient amounts confer a health benefit on the host. In the context of COVID-19, the use of probiotics might therefore plausibly help in the prevention of pulmonary infections. It is also important to consider that antibiotics and antivirals are often administered in patients with COVID-19, which could result in alteration of the gut microbiota. 9 Thus, a recent study in Hong Kong noted significant changes in the faecal microbiomes among 15 COVID-19 patients. 10 Whether the intestinal microbial dysbiosis is specific to SARS-CoV-2 infection or is exacerbated by antibiotic use is not known. Nevertheless, this study showed that baseline abundance of Bacteroidetes species had an inverse correlation with COVID-19 severity and faecal viral load of SARS-CoV-2. They also discovered that Actinomyces viscosus, an opportunistic pathogen of the upper respiratory tract, is present in the gut of COVID-19 patients. This further supports the potential benefit of probiotics following the gut-lung connection hypothesis.

The future of probiotics in COVID-19 is still unclear and there is still much to be learned. In particular, there is a need to identify specific strains which are beneficial as each strain may have a specific effect. Nevertheless, the investigation of probiotic therapies during the pandemic could be reasonable. Interestingly, they are already being used in patients with severe COVID-19 disease in China. 9 If others should follow-that, we still have to discover.

Declaration of personal interests: None. 

Probiotics in the intensive care unit

Probiotics and digestive disease

Probiotics and COVID-19: one size does not fit all

Respiratory antiviral immunity and immunobiotics: beneficial effects on inflammation-coagulation interaction during influenza virus infection

Probiotics for preventing acute upper respiratory tract infections

Probiotics for the prevention of ventilator-associated pneumonia: a meta-analysis of randomized controlled trials

Novel coronavirus infection and gastrointestinal tract

Alterations in gut microbiota of patients with COVID-19 during time of hospitalization